Status In progress
Process CDF Review
ID number 1584

Project Team

Project lead Kate Moore

Email enquiries


Key events during the development of the guidance:

Date Update
30 August 2019 In progress, Pembrolizumab within its marketing authorisation for non-small cell lung cancer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance